iTeos Therapeutics logo
iTeos Therapeutics ITOS

Quarterly report 2025-Q2
added 08-06-2025

report update icon

iTeos Therapeutics Financial Statements 2011-2026 | ITOS

Annual Financial Statements iTeos Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

293 M 421 M 555 M 1.64 B 779 M - - - - - - - - -

Shares

40.5 M 35.8 M 35.6 M 35.2 M 24.3 M - - - - - - - - -

Historical Prices

7.24 11.8 15.6 46.6 33.8 - - - - - - - - -

Net Income

-134 M -113 M 96.7 M 215 M -38 M -22.5 M -18.1 M - - - - - - -

Revenue

35 M 12.6 M 268 M 345 M - - - - - - - - - -

Operating Income

-160 M -151 M 126 M 245 M -45.2 M -28 M - - - - - - - -

Interest Expense

3.11 M 4.08 M 7.79 M 1.3 M -48 K -85 K - - - - - - - -

EBITDA

-158 M -150 M 127 M 246 M -38.8 M -22.7 M -17.3 M - - - - - - -

Operating Expenses

195 M 164 M 141 M 99.9 M 39.3 M 23.3 M 17.8 M - - - - - - -

General and Administrative Expenses

49.1 M 50.4 M 43.9 M 40.5 M 15.3 M 8.84 M 4.31 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement iTeos Therapeutics

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

43.6 M 43.2 M 36.6 M 43.1 M 39.7 M 35.8 M 35.8 M 35.8 M 35.8 M 35.7 M 35.6 M 35.6 M 35.5 M 35.5 M 35.5 M 35.2 M 35.1 M 35.1 M 35 M 24.3 M 349 K 257 K 257 K 186 K 186 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-78.7 M -34.6 M - -45.4 M -7.13 M -38.2 M - -32.2 M -34.3 M -15.6 M - 991 K 5.63 M 69.6 M - 69.6 M -26.5 M -13.5 M - -10.7 M -7.2 M -5.25 M - -6.92 M -5.76 M -4.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - 35 M - - - - 12.6 M - 19.5 M 41.7 M 153 M - 104 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-83.8 M -40 M - -48.8 M -14.2 M -47.2 M - -43.3 M -42.6 M -24.9 M - -15.2 M 3.34 M 121 M - 79.4 M -29.3 M -18.7 M - -13.5 M -8.53 M -8.24 M - -7.7 M -6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-585 K -1.34 M - -3.13 M 67 K 2.09 M - 771 K 326 K 1.65 M - 9.28 M 3.61 M -2.12 M - -8.48 M 60 K 240 K - 265 K 12 K -42 K - -2 K -47 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- -39.7 M - -48.5 M -13.9 M -46.9 M - -43.1 M -42.4 M -24.7 M - -15 M 3.54 M 121 M - 79.6 M -29.1 M -18.6 M - -13.4 M -8.43 M -8.12 M - -7.23 M -5.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

83.8 M 40 M - 48.8 M 49.2 M 47.2 M - 43.3 M 42.6 M 37.5 M - 34.7 M 38.4 M 31.7 M - 24.9 M 29.3 M 18.7 M - 13.5 M 8.53 M 8.24 M - 7.7 M 6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

10.2 M 11 M - 12.1 M 12.5 M 12.7 M - 12.6 M 13.4 M 11.9 M - 10.8 M 11.5 M 10.6 M - 8.76 M 15.1 M 7.05 M - 4.8 M 2.39 M 2.42 M - 2.7 M 2.09 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements iTeos Therapeutics ITOS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting iTeos Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.93 0.88 % $ 219 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.93 0.51 % $ 5.07 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.14 0.36 % $ 443 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.39 4.5 % $ 230 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.06 1.94 % $ 1.46 B usaUSA
argenx SE argenx SE
ARGX
$ 749.68 0.44 % $ 25 B niderlandNiderland
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.93 1.27 % $ 3.04 B usaUSA
Arvinas Arvinas
ARVN
$ 11.36 4.7 % $ 805 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 61.99 1.57 % $ 8.29 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Assembly Biosciences Assembly Biosciences
ASMB
$ 29.09 0.28 % $ 326 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.13 15.26 % $ 35.3 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 5.19 -3.36 % $ 44.7 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 5.0 0.2 % $ 62.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.05 2.79 % $ 2.16 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.41 -0.35 % $ 375 M britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 411.97 -0.2 % $ 31.2 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.65 -1.12 % $ 16.6 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioCardia BioCardia
BCDA
$ 1.18 -1.67 % $ 7.87 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 9.59 6.26 % $ 1.98 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 3.05 1.51 % $ 260 M usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 9.46 -3.47 % $ 612 M usaUSA
BioVie BioVie
BIVI
$ 1.46 2.81 % $ 2.16 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.32 4.98 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 56.04 0.96 % $ 10.7 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.64 0.5 % $ 27.2 B germanyGermany
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.18 -0.42 % $ 14.4 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.5 8.57 % $ 683 M britainBritain